OBJECTIVE: Thromboembolism is one of the most common and serious complications associated with the endovascular embolization of intracranial aneurysms. We report our clinical experiences with intra-arterial tirofiban infusion during aneurysm embolization. METHODS: The clinical, radiological, and laboratory data of 24 patients harboring 25 aneurysms (25 procedures) who underwent intra-arterial tirofiban infusion for thromboembolism during the endovascular treatment of intracranial aneurysms were reviewed retrospectively. Thrombi or emboli were resolved by superselective intra-arterial tirofiban infusion via a microcatheter. RESULTS: The study cohort comprised 14 unruptured and 11 ruptured aneurysms. Intra-arterially infused tirofiban doses ranged from 0.2 to 1.0 mg (mean +/- standard deviation, 0.64 +/- 0.25 mg). Thromboemboli were resolved, and arteries were recanalized on all occasions except one: a case of distal middle cerebral artery embolism. No hemorrhagic complications related to intra-arterial tirofiban infusion occurred. CONCLUSION: Intra-arterial tirofiban delivery appears to be a safe and effective treatment modality when thromboembolism is encountered during the endovascular treatment of intracranial aneurysms.
OBJECTIVE:Thromboembolism is one of the most common and serious complications associated with the endovascular embolization of intracranial aneurysms. We report our clinical experiences with intra-arterial tirofiban infusion during aneurysm embolization. METHODS: The clinical, radiological, and laboratory data of 24 patients harboring 25 aneurysms (25 procedures) who underwent intra-arterial tirofiban infusion for thromboembolism during the endovascular treatment of intracranial aneurysms were reviewed retrospectively. Thrombi or emboli were resolved by superselective intra-arterial tirofiban infusion via a microcatheter. RESULTS: The study cohort comprised 14 unruptured and 11 ruptured aneurysms. Intra-arterially infused tirofiban doses ranged from 0.2 to 1.0 mg (mean +/- standard deviation, 0.64 +/- 0.25 mg). Thromboemboli were resolved, and arteries were recanalized on all occasions except one: a case of distal middle cerebral artery embolism. No hemorrhagic complications related to intra-arterial tirofiban infusion occurred. CONCLUSION: Intra-arterial tirofiban delivery appears to be a safe and effective treatment modality when thromboembolism is encountered during the endovascular treatment of intracranial aneurysms.
Authors: Jin Ho Hwang; Hong Gee Roh; Young Il Chun; Hyun-Seung Kang; Jin Woo Choi; Won-Jin Moon; Joon Cho; Chang Taek Moon; Young Cho Koh Journal: Neuroradiology Date: 2010-06-24 Impact factor: 2.804
Authors: Pankajavalli Ramakrishnan; Albert J Yoo; James D Rabinov; Christopher S Ogilvy; Joshua A Hirsch; Raul G Nogueira Journal: Interv Neurol Date: 2013-10
Authors: J M Ospel; P Brouwer; F Dorn; A Arthur; M E Jensen; R Nogueira; R Chapot; F Albuquerque; C Majoie; M Jayaraman; A Taylor; J Liu; J Fiehler; N Sakai; K Orlov; D Kallmes; J F Fraser; L Thibault; M Goyal Journal: AJNR Am J Neuroradiol Date: 2020-09-17 Impact factor: 3.825
Authors: Jacques Sedat; Yves Chau; Lydiane Mondot; Richard Chemla; Michel Lonjon; Bernard Padovani Journal: Neuroradiology Date: 2013-11-27 Impact factor: 2.804
Authors: Jin Sue Jeon; Seung Hun Sheen; Gyojun Hwang; Suk Hyung Kang; Dong Hwa Heo; Yong Jun Cho Journal: J Cerebrovasc Endovasc Neurosurg Date: 2012-03-31
Authors: Hyo Sub Jun; Jun Hyong Ahn; Ji Hee Kim; Jae Keun Oh; Joon Ho Song; In Bok Chang Journal: Interv Neuroradiol Date: 2016-04-11 Impact factor: 1.610